ÇERKEZKÖY-2
DEVA Holding Çerkezköy-II Manufacturing Facility, which has enclosed facilities of 50,270 m² established on an area of 67,551 m2 in Çerkezköy Organized Industrial Zone, at a distance of approximately 110 km from Istanbul, is made up of modern buildings manufacturing solid oncology products, sterile liquid oncology products, animal health products and APIs.
Çerkezkoy-II Manufacturing Facility also houses the Biotechnology Building, the Central Stability Building, and the R&D Center Buildings, each dedicated to their respective fields of operation.
The production site approval for the High Potent Production Building, for which construction and equipment installations have been completed, was obtained in the first quarter of 2023, initiating operations.
Solid Oncology Manufacturing Unit
Products in the form of tablets and capsules are manufactured in the Solid Oncology Manufacturing Unit.
The total quantity manufactured, which was 1.3 million units in 2022, increased by 42% to 1.8 million units in 2023.
Of a total of 1.84 million units manufactured in 2023, 0.57 million units were manufactured in the form of capsules and 1.27 million units in the form of tablets.
In addition, 0.2 million of 1.27 million units of products manufactured in tablet form and 0.2 million of 0.57 million capsules were manufactured for the European market.
Sterile Liquid Oncology Manufacturing Unit
Products in the form of sterile liquid and sterile lyophilized powder are manufactured in the Sterile Liquid Oncology Manufacturing Unit.
The total quantity manufactured in the unit, which was 1 million units in 2022, was realized as 0.58 million units in 2023.
Of 0.58 million units of products, 0.41 million units were liquid products and 0.17 million units were lyophilized products.
Non-Sterile (Solid) Animal Health Products Manufacturing Unit
Animal health products are manufactured in the NonSterile (Solid) Animal Health Products Manufacturing Unit, 7 of which are in tablet form, 11 in powder form filled in small and large sachets.
The total quantity manufactured in the unit, which was 1.47 million units in 2022, realized as 0.32 million units in 2023. 0.27 million units of these products are in tablet form while 0.05 million units are in powder form.
API (Active Pharmaceutical Ingredient) Manufacturing Units
The facility has two physically separate and independent API Manufacturing Units for manufacture of non-betalactam API and oncolytic API.
The quantity of the API manufactured was 2,749 kg in 2022, while it was 3,142 kg in 2023.
Of the total API quantity of 3,142 kg manufactured in 2023, 2,261 kg was non-beta-lactam API while 881 kg was oncolytic API.
In API manufacturing, the toxic gases arising from reaction are neutralized before being released to the atmosphere to minimize the environmental effects resulting from manufacturing activities.
To sum up, the total quantity of finished products manufactured in the Çerkezkoy-II Facility of DEVA Holding was 3.76 million units in 2022, while it was 2.74 million units in 2023.
The total capacity utilization rate of the Çerkezkoy Manufacturing Facilities is 89%.
